Montreal April 5, 2017.

Searidge foundation and MontrealEpiTerapia announced today the launch of a new innovative program for treating drug addiction developed by DHEA Horizon Inc. Searidgecenters are amongst Canada’s best alcohol and drug rehab centersrecognized for excellence in evidence-based psychotherapy and a high rate of successful recovery. Montreal EpiTerapia is a company founded by McGill epigenetics pioneer Professor Moshe Szyf to promote novel therapies for cancer and behavioral diseases. The DHEA Horizon program is an add-on to the excellent holistic program that is currently the mainstay of Searidge rehab centers. The program uses a novel algorithm developed by DHEA horizon scientists, which takes into account personal data and key physical and psychological parameters of each patient, calculating the optimal dose of DHEA and length of treatment. The personal profile of each individual enables medical caregivers to monitor progress, manage treatment, and even predict the length of treatment needed for each patient and the probability of relapse. This program combines concepts of personalized medicine and treatment with a natural product to reverse the underlying mechanism driving drug craving and addiction. The discovery that led to the DHEA program was made by a team of Neuropharmacologists at Bar Ilan university in Ramat Gan Israel led by professor Gal Yadid working on animal models of drug craving. The scientists discovered that DHEA could almost completely reverse drug craving in these animals. The remarkable results in animals were translated to a human clinical study. In a double-blind, placebo-controlled study in adult polydrug users, the follow-up conducted 16 months after the completion of rehab revealed that relapse rates of DHEA-treated subjects were only 11.5%. No adverse symptoms were found.
“My own experience of more than 25 years in the field, and my collaboration with cognitive psychologists 
andneuro-pharmacologists, affirms a vital lesson. Promising results in treating addiction are often linked to the integration of pharmacology and psychology,” says Eitan Eckstein the Director of Retorno a rehab facility in Israel that participated in the clinical trial. Eckstein added that: “The most encouraging outcomes I have experienced are the result of our integration of the steroidal pro-hormone DHEA dietary supplement as a component of our holistic treatment program. At my rehabilitation center, Retorno, we implemented a complementary course of treatment, supervised by the Israel Ministry of Health and Yehuda Abarbanel Mental Health Center. Our resident patients were given DHEA every day for 3 months. The result? Approximately 30% improvement in recovery rates. The study affirmed our A-HA moment.”
Catherine Cosgrove the director of Searidge expressed her excitement with the new program and added that “We hope that this new program will add significantly to our current outstanding slate of programs and we are excited about 
combiningpersonalized medicine pharmacology and psychotherapy which our institution has long believed is the future of drug addiction.”

Harnessing the potential of genetics and epigenetics for new therapeutics and diagnostics